Abstract
Bladder cancer (BLCA) is among the most malignant types of cancer. At present, the prognostic tools available for this disease are insufficient. In the present study, the transcriptome of 1,049 BLCA samples from four datasets from the Gene Expression Omnibus and The Cancer Genome Atlas (TCGA) were analyzed. By utilizing the RNA-seq data provided by TCGA, a risk score staging system model was built to predict the outcome of patients with BLCA using random forest variable hunting and Cox multivariate regression. A total of 7 genes, including zinc finger protein 230, Bcl2-like 14, AHNAK, transmembrane protein 109, apolipoprotein L2, advanced glycation end-product specific receptor and amine oxidase, copper containing 2 were identified as predicting the survival time of patients with BLCA. The patients with a low risk score had a significantly higher survival rate than those with a high-risk score both in the training and validation datasets. Association analyses between risk score and other clinical information were additionally performed; it was demonstrated that the risk score was significantly associated with pathological stage. A nomogram was plotted to compare risk score and other clinical information. The risk score spanned ...Continue Reading
References
Nov 9, 2002·Bioinformatics·Carlo ColantuoniJonathan Pevsner
Feb 13, 2004·Bioinformatics·Laurent GautierRafael A Irizarry
Oct 4, 2005·Proceedings of the National Academy of Sciences of the United States of America·Aravind SubramanianJill P Mesirov
Feb 7, 2007·Breast Cancer Research : BCR·Meng-Lay LinToyomasa Katagiri
Apr 17, 2010·PloS One·Veikko SalomaaStefan Blankenberg
Mar 19, 2011·BMC Bioinformatics·Xavier RobinMarkus Müller
May 11, 2012·Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology·Margaret R SpitzChristopher I Amos
Jul 20, 2012·Advances in Urology·Matteo SantoniGiorgio Santoni
Nov 21, 2013·International Journal of Oncology·Hitomi SudoTsuneo Saga
Jan 23, 2014·BJU International·Gregory B BousteadUNKNOWN Section of Oncology, BAUS
Aug 31, 2014·Cellular Signalling·T A DavisA-M Engelbrecht
Jan 7, 2015·CA: a Cancer Journal for Clinicians·Rebecca L SiegelAhmedin Jemal
May 16, 2015·Journal of Surgical Oncology·Jinfeng WangChuanxin Wang
Dec 18, 2015·Melanoma Research·Hilary M SheppardP Rod Dunbar
Jan 9, 2016·CA: a Cancer Journal for Clinicians·Rebecca L SiegelAhmedin Jemal
Apr 9, 2016·International Journal of Hyperthermia : the Official Journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group·Esmee I M L LiemTheo M de Reijke
Aug 6, 2016·Journal of Computational Biology : a Journal of Computational Molecular Cell Biology·Enrique J Deandrés-GalianaStephen T Sonis
Oct 8, 2016·Oncotarget·Jianqi YangRory A Fisher
Nov 20, 2016·Oncotarget·Virginia UrquidiSteve Goodison
Nov 23, 2016·Nature Reviews. Clinical Oncology·Samuel A Funt, Jonathan E Rosenberg
Dec 15, 2016·Oncotarget·Yunhai LiGuosheng Ren
Dec 17, 2016·Cancer Biomarkers : Section a of Disease Markers·Zehui HongTing Xu
Dec 18, 2016·The Journal of Urology·Laimonis KavalierisYair Lotan
Dec 31, 2016·Bladder Cancer·Lakshminarayanan Nandagopal, Guru Sonpavde
Mar 16, 2017·Bioinformation·Fereshteh IzadiNadali Babaeian Jelodar
May 2, 2017·European Urology·Viktor SoukupRichard Zigeuner